Syndecan-1 a Surrogate Marker for IBD

Study Overview
=================
Brief Summary
-----------------
Syndecan-1 is a protein on the surface intestinal cells. previous studies proved low levels of mucosal syndecan-1 levels on the surface of intestinal cells is patients with acute and chronic inflammation due to inflammatory bowel disease. this protein might shed from cell surface to the serum. The investigators wish to prove that elevated serum levels of syndecan-1 may be predictive of disease presence, extent and severity, that buy taking a simple blood sample from patients diagnosed with inflammatory bowel disease and comparing to normal subjects and to other markers.

Detailed Description
-----------------
One of the main hypothesis for the etiology of Inflammatory bowel disease (IBD) is an inappropriate and ongoing activation of the mucosal immune system in response to the presence of normal luminal flora. This aberrant response is most likely facilitated by defects in both the barrier function and the mucosal immune system of the intestinal epithelium. Syndecans are a class proteoglycans that take part in both cell adhesion and growth factor binding. Of the four known syndecan core proteins, syndecan-1 (CD138) and one of the best studied of this group and is also the relevant to the this study as it is expressed on the basolateral surface of columnar epithelial cells of the colon. Syndecan-1 functions as an integral membrane protein that participates in cell proliferation, cell migration and cell matrix interactions in the GI tract. Evidence for a reduction of syndecan-1 expression in the regenerating epithelium that overlies inflamed tissue was reported in both acute and chronic inflammation. This protein that is lost from the inflamed mucosal membrane might shed to the serum. Elevated serum levels of syndecan-1 may be predictive of disease presence and extent.

Official Title
-----------------
Syndecan-1 as a Surrogate Marker for Inflammatory Bowel Disease

Conditions
-----------------
Inflammatory Bowel Diseases

Intervention / Treatment
-----------------
* Procedure: blood sample
* Procedure: Blood sample - venous blood 10 ml.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: informed consent no other concurrent inflammatory disease formal diagnosis of inflammatory bowel disease i.e Crohn's disease, Ulcerative colitis Exclusion Criteria: pregnancy fever at time of sample taking

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Crohn's, ulcerative colitis<br>Patients with diagnosed with Crohn's disease or ulcerative colitis who agreed to participate in the study and singed informed consent and answered a Crohn's disease activity index questioner for Crohn's disease or the ulcerative colitis activity index questioner for ulcerative colitis. | Procedure: Blood sample - venous blood 10 ml.<br>* venous blood sample from a peripheral vein, 10ml total for blood count, total serum : protein, albumin, LDH, C-reactive protein,syndecan-1<br>* Other names: Syndecan-1;|
| No disease<br>Healthy subjects with no known inflammatory disease. For basal serum levels of syndecan 1 | Procedure: blood sample<br>* Blood sample from a peripheral vein, 10ml total for blood count, total serum : protein, albumin, LDH, C-reactive protein,syndecan-1<br>* Other names: Syndecan-1;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Elevated serum syndecan-1 levels as a bio marker for IBD | elevated serum syndecan-1 levels in patients with IBD compared to control | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum syndecan-1 levels and disease severity Crohn's | Relationship between clinical data CDAI in crohn's patients and serum syndecan-1 levels | one year | 
| Serum syndecan-1 levels and disease severity ulcerative colitis | Relationship between clinical data UCAI ulcerative colitis patients and serum syndecan-1 levels | one year | 
| Serum syndecan-1 levels and C reactive protein(CRP) Crohn's | Relationship between lab data CRP levels in crohn's patients and serum syndecan-1 levels | one year | 
| Serum syndecan-1 levels and C reactive protein(CRP) ulcerative colitis | Relationship between serum CRP levels and serum syndecan-1 levels in patients with ulcerative colitis | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Crohn's disease, ulcerative colitis, Syndecan-1